COVID-19 Emergency Ventilator

In response to the COVID-19 outbreak, Imperial’s experts in medical device design (bioengineering) – and a clinician treating infected patients – have designed an emergency ventilator that can be built to meet MHRA and FDA requirements using generic parts.  JAMVENT provides a simple, low-cost solution to ventilator shortages worldwide, particularly for health services in developing countries. Plus the robust design also makes it suitable for long term use beyond current COVID-19 needs.

The design document for the JAMVENT ventilator can be requested by those wishing to develop ventilators for their local healthcare providers and includes a list of parts and a software spec.

We welcome enquiries from health organisations, manufacturers and donors interested in working with us to take JAMVENT from design to manufacture.

 

Design benefits

  • Long term use – not specific to the COVID-19 crisis
  • Easy to manufacture from low cost components (estimated at around £1,500 in the UK)
  • Does not require specific pressure transducers or solenoids
  • Parts can be sourced from various manufacturers – avoiding supply-chain bottlenecks
  • No specialist or medical supply chain components – and no balloons
  • Simple electronics
  • Doesn’t require gas to drive it – unlike some others – which is critical where gas supply is limited.
  • Employs fluid mechanical design principles

 

Ventilator design meets clinicians needs

  • PEEP controllable electronically
  • Pressure Regulated Volume Control (PRVC) mode
  • Supports spontaneous breath
  • Maintains PEEP during suctioning

Performance evidence

Evidence that the JAMVENT prototype can perform to MHRA and ISO 80601 tests can be downloaded here.

It also highlights PRVC and spontaneous mode performance and how it can maintain PEEP during suctioning – critical functions of ICU ventilators for COVID-19 patients.

 

JAMVENT ventilator in action – click to view a video

 

Ventilator system

 


Creators of the emergency ventilator design

  • Project and Technical Lead – Dr Joseph Sherwood – RAEng Research Fellow, Department of Bioengineering. Research areas include biofluid mechanics, flow measurement/control, device design for research.
  • Clinical Lead – Dr. Jakob Mathiszig-Lee – Honorary Research Fellow and Senior Anaesthetic Registrar at the Royal Brompton Hospital. Department of Surgery and Cancer.
  • Project Manager – Prof James Moore – The Bagrit Chair in Medical Device Design, Department of Bioengineering. Research areas include biofluid mechanics, cardiovascular device design, device translation.
  • Co-Technical Lead – Dr Michael Madekurozwa, Department of Bioengineering. Research areas include experimental biofluid dynamics, design and implementation of tools, hardware and software for use in research.

Related Insights

The search for a cure

The search for a cure

For the past 25 years Imperial has been at the heart of the hunt for a cure for HIV. This is the story of that search – of the highs, the lows, the setbacks and the breakthroughs. read more

Pandemics and privacy

Pandemics and privacy

Contact tracing apps will take and keep some data from users. This insight discusses ways of minimising privacy implications. read more

Healthcare AI

Healthcare AI

AI not only automates problem-solving carried out by doctors, but can also make quicker and better decision and apply problem-solving techniques that humans alone could not. read more

Related case studies

Hepatitis C genotype and drug resistance testing

Hepatitis C genotype and drug resistance testing

Genotype and resistance testing for new direct-acting antiviral (DAA) drugs designed to treat Hepatitis C virus (HCV). read more

Imperial College London Diabetes Centre

Imperial College London Diabetes Centre

The Imperial College London Diabetes Centre was established in Abu Dhabi, in 2006, by Mubadala and experts from Imperial to address the demand for diabetes care in the UAE. With continued support from Imperial, the centre now operates three branches across Abu Dhabi and Al Ain and public health initiatives. read more

Cystic Fibrosis clinical advisory board

Cystic Fibrosis clinical advisory board

Our consultants shared their expertise in Cystic Fibrosis (CF), drug development and clinical trials to help Proteostasis Therapeutics assess the combination of compounds aimed at treatments to improve lung function. read more

Latest news

Cricketer set a £1million batting challenge

Cricketer set a £1million batting challenge

A leading cricketer has been offered £1million to strike a ball clear of the Lord’s Pavilion, using a new Mongoose bat tested by Imperial Consultants. read more

Using ultrasound to assess women with pelvic pain, including endometriosis – 23 Sept

Using ultrasound to assess women with pelvic pain, including endometriosis – 23 Sept

ISUOG approved webinar for radiologists, sonographers, gynaecologists, sonologists and trainees providing best practice for using ultrasound for women presenting with pelvic pain and the clinical application of current knowledge on the diagnosis of deep endometriosis. 12 noon UK. read more

Imperial’s COVID-19 vaccine explained

Imperial’s COVID-19 vaccine explained

As the first trials of Imperial’s COVID-19 vaccine candidate got underway in June, Professor Robin Shattock, Dr Katrina Pollock and Dr David Owen explain how the vaccine works, how it’s being trialled, and plans to help it reach populations around the world, if it proves to be effective in protecting people against COVID-19. read more